These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29914022)

  • 21. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
    Liu E; Schmidt ME; Margolin R; Sperling R; Koeppe R; Mason NS; Klunk WE; Mathis CA; Salloway S; Fox NC; Hill DL; Les AS; Collins P; Gregg KM; Di J; Lu Y; Tudor IC; Wyman BT; Booth K; Broome S; Yuen E; Grundman M; Brashear HR;
    Neurology; 2015 Aug; 85(8):692-700. PubMed ID: 26208959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Abushouk AI; Elmaraezy A; Aglan A; Salama R; Fouda S; Fouda R; AlSafadi AM
    BMC Neurol; 2017 Apr; 17(1):66. PubMed ID: 28376794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease.
    Lu M; Brashear HR
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):326-335. PubMed ID: 29920980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
    Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
    Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.
    Malpas CB; Vivash L; Genc S; Saling MM; Desmond P; Steward C; Hicks RJ; Callahan J; Brodtmann A; Collins S; Macfarlane S; Corcoran NM; Hovens CM; Velakoulis D; O'Brien TJ
    J Alzheimers Dis; 2016 Jul; 54(1):223-32. PubMed ID: 27447428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
    Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
    Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3 trial of IV immunoglobulin for Alzheimer disease.
    Relkin NR; Thomas RG; Rissman RA; Brewer JB; Rafii MS; van Dyck CH; Jack CR; Sano M; Knopman DS; Raman R; Szabo P; Gelmont DM; Fritsch S; Aisen PS;
    Neurology; 2017 May; 88(18):1768-1775. PubMed ID: 28381506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
    Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
    Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
    Cummings JL; Zhong K; Kinney JW; Heaney C; Moll-Tudla J; Joshi A; Pontecorvo M; Devous M; Tang A; Bena J
    Alzheimers Res Ther; 2016 Jan; 8():4. PubMed ID: 26822146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease.
    Hu C; Adedokun O; Ito K; Raje S; Lu M
    J Clin Pharmacol; 2015 Feb; 55(2):221-9. PubMed ID: 25187399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.